Combination therapy for erectile dysfunction: A randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction

International Journal of Impotence Research

Volumn 14, Issue 1, 2002, Pages 54-60

  Lammers, P I ^a   Rubio Aurioles, E ^b   Castell, R ^c   Castaneda, J ^c   Ponce de Leon, R ^d   Hurley, D ^d   Lipezker, M ^d   Loehr, L A ^d   Lowrey, F ^a   Hedlund, P ^a  

^a Zonagen Inc   (United States)

^b Asociación Mexicana para la Salud Sexual México   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d Estadisticos y Clinicos Asociados   (Mexico)

Author keywords

Apomorphine; Erectile dysfunction; Impotence; Oral combination; Papaverine; Pharmacodynamics; Phentolamine; Safety

Indexed keywords

APOMORPHINE; CYTOCHROME P450 INHIBITOR; NITRIC ACID DERIVATIVE; PAPAVERINE; PHENTOLAMINE MESYLATE; SILDENAFIL; TRICOMBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-ANTAGONISTS; APOMORPHINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; IMPOTENCE; MALE; PAPAVERINE; PHENTOLAMINE; PIPERAZINES; SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 18244381593     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900816     Document Type: Article

References (0)